| Website | biosensia.com |
| Category | BioTech |
| Phone | +353 1 7163650 |
| Employees | |
| Founded | 2006 |
| Description | in-vitro diagnostics company |
| Total | $4.13M |
| Unattributed, 2/08 Street Capital Enterprise Ireland Seroba Kernel Atlantic Bridge | $2.93M |
| Unattributed, 12/11 ACT Venture Capital Seroba Bioventures Atlantic Bridge | €1.2M |
Biosensia is a Point-of-Care in-vitro diagnostics company that has a novel point-of-care platform, RapiPlex, available for licensing.
RapiPlex combines highly innovative technologies to produce a practical, rapid, multiplexing POC in-vitro diagnostics (IVD) platform, enabling access to a broad range of diagnostic applications.
Its component chip and cartridge system are compatible with a variety of common biological sample types, including whole blood, serum, saliva, urine and nasal/genital swabs.
